Ansell E, Fazzone T, Festenstein R, Johnson E S, Thavapalan M, Wilkinson M, Wozniak I
City of London Migraine Clinic, UK.
Cephalalgia. 1988 Dec;8(4):269-72. doi: 10.1046/j.1468-2982.1988.0804269.x.
Nimodipine is a compound that is thought to block the influx of calcium through channels in vascular smooth muscle. This paper describes a double-blind parallel-group comparison of 40 mg nimodipine three times a day and placebo. Sixty-eight patients received treatment after a run-in period of 2 months, and of these, 57 completed 8 weeks or more of the trial. All but five of these completed the full 6-month trial. The nimodipine and placebo groups showed no significant differences in the frequency of attacks, severity or duration of headache, or gastrointestinal or other symptoms.
尼莫地平是一种被认为可通过血管平滑肌通道阻止钙内流的化合物。本文描述了每日三次服用40毫克尼莫地平与安慰剂的双盲平行组对照试验。68名患者在2个月的导入期后接受治疗，其中57名完成了8周或更长时间的试验。除5人外，其余所有人都完成了为期6个月的完整试验。尼莫地平组和安慰剂组在发作频率、头痛的严重程度或持续时间，或胃肠道及其他症状方面均无显著差异。
